Konferenzpaper
Autorenliste: Laube, H
Jahr der Veröffentlichung: 2003
Seiten: 2-6
Zeitschrift: Medizinische Klinik
Bandnummer: 98
ISSN: 0723-5003
Konferenz: Symposium on Reduction of Postpradial Blood Sugar for Reduction of Cardiovascular Risks
Verlag: Springer Verlag (Germany)
Abstract:
Acarbose is a first-line treatment for newly diagnosed patients with type 2 diabetes, those who have high postprandial blood glucose and for patients in whom dietary treatment alone provides inadequate glycemic control. Acarbose lowers blood glucose when administered as monotherapy and in combination with other antidiabetic drugs. It reliably reduces levels of glycated hemoglobin (HbA(1c)) by 0.9% and positively affects other parameters of the metabolic syndrome. In patients with impaired glucose tolerance, it reduces cardiovascular endpoints significantly by 49%. There are no serious side effects. Gastrointestinal adverse effects decrease considerably by a stepwise and individual dosage adjustment during long-term treatment and good dietary discipline.
Zitierstile
Harvard-Zitierstil: Laube, H. (2003) Acarbose, a reliable therapeutic principle, Medizinische Klinik, 98, pp. 2-6
APA-Zitierstil: Laube, H. (2003). Acarbose, a reliable therapeutic principle. Medizinische Klinik. 98, 2-6.
Schlagwörter
ACARBOSE; ALPHA-GLUCOSIDASE INHIBITION; DIABETES-MELLITUS; etabolic syndrome; MONOTHERAPY; NIDDM PATIENTS; PLACEBO; postprandial hyperglycemia m; therapeutic benefit
